Goserelin Implant Regimen Switching for Breast Cancer Adherence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing goserelin implant dosing regimens for breast cancer treatment face challenges in patient compliance and require frequent administration, leading to potential nonadherence and increased healthcare visits.
Innovation Solution
A dosing regimen that involves concomitant administration of a 3.6 mg goserelin acetate implant with chemotherapy cycles, followed by a switch to a 10.8 mg implant every 84 to 108 days for improved compliance and reduced frequency of administration, addressing nonadherence and enhancing treatment duration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a 3.6 mg goserelin implant is administered monthly, then ovarian suppression is maintained, but patient compliance deteriorates due to frequent administration requirements
Solution Approach 1:
The treatment regimen is segmented into two phases: an initial phase with 3.6 mg monthly implants to establish ovarian suppression, followed by a maintenance phase with 10.8 mg quarterly implants. This segmentation allows the treatment to adapt to patient compliance patterns while maintaining therapeutic efficacy.
Solution Approach 2:
The dosing regimen dynamically transitions from frequent monthly administrations to less frequent quarterly administrations after the initial phase. This dynamic adjustment maintains suppression efficacy while reducing the burden on patients, thereby improving compliance.
2Reliability
If a 3.6 mg goserelin implant is administered monthly, then hormone receptor positive breast cancer is treated, but treatment duration deteriorates due to patient nonadherence
Solution Approach 1:
The initial phase of monthly 3.6 mg administrations serves as a preliminary action to establish reliable ovarian suppression and treatment response before transitioning to the maintenance phase. This preliminary establishment of efficacy ensures that when the dosing interval is extended, the therapeutic benefit is already secured.
3Ease of operation
If a 10.8 mg goserelin implant is administered quarterly, then patient compliance improves, but the regimen is not approved for breast cancer treatment in the US
Solution Approach 1:
The regimen segments the use of the 10.8 mg implant into a maintenance phase following initial 3.6 mg administrations. This segmentation allows the higher-dose, longer-interval implant to be used in a controlled manner that addresses compliance issues while managing regulatory considerations.
Solution Approach 2:
The regimen changes the dosing parameters from 3.6 mg monthly to 10.8 mg quarterly after the initial phase. This parameter change optimizes compliance by reducing administration frequency while maintaining therapeutic effect through the cumulative dosing strategy.
4Reliability
If frequent monthly administrations are required, then ovarian suppression is maintained, but healthcare utilization increases
Solution Approach 1:
The regimen dynamically adjusts the administration frequency from monthly to quarterly after the initial phase. This dynamic change reduces the number of healthcare visits required for implantation and monitoring, thereby improving healthcare utilization efficiency while maintaining suppression through the optimized dosing interval.
Data Source
AI summary
Described herein are methods of treating hormone receptor positive breast cancer in a patient which include concomitantly administering an initial neoadjuvant or adjuvant IV chemotherapy cycle and an initial dose of a 3.6 mg goserelin acetate implant to the patient, or concomitantly administering an initial dose of a 3.6 mg goserelin acetate implant to the patient with a first of a plurality of long-term IV chemotherapy cycles. After one or more doses of the 3.6 mg goserelin acetate implant, the 3.6 mg goserelin acetate implant is discontinued, and the patient is then administered a 10.8 mg goserelin implant once every 84 to 108 days. Also included are methods of improving patient compliance, increasing duration of treatment, and/or reducing the need for oophorectomy in a patient with hormone receptor positive breast cancer by administering a 3.6 mg goserelin acetate implant to the patient, and upon the patient becoming nonadherent, the 3.6 mg goserelin acetate implant is discontinued, and the patient is then administered a 10.8 mg goserelin implant once every 84 to 108 days.